Chemistry:MDMB-FUBINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C22H24FN3O3 |
| Molar mass | 397.450 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with Ki values of 1.14 nM at CB1 and 0.1228 nM at CB2 and EC50 values of 0.2668 nM at CB1 and 0.1411 nM at CB2,[1] and has been sold online as a designer drug.[2][3] Its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (Ki = 0.14 nM, EC50 = 2.42 nM).[4][5] The structure of MDMB-FUBINACA contains the amino acid, 3-methylvaline[6] or tert-leucine methyl ester.
Side effects
There have been a large number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid, mainly in Russia and Belarus. MDMB-FUBINACA was first reported in 2014 and quickly gained a reputation as the most deadly synthetic cannabinoid drug sold by 2015.[7] Up to 700 hospitalisations and 25 deaths were initially linked to MDMB-FUBINACA in media and government reports, and subsequent testing confirmed that at least 1000 hospitalisations and 40 deaths had occurred as a consequence of intoxication by MDMB-FUBINACA as of March 2015.[8][9]
Legal status
In the United States, MDMB-FUBINACA is a Schedule I controlled substance.[10]
As of October 2015, MDMB-FUBINACA is a controlled substance in Belarus, Russia,[11] and China.[12]
In July 2021 it was included in Table II-A of the list of prohibited drugs of Portugal.
See also
- 5F-AB-PINACA
- 5F-ADB
- 5F-AMB
- 5F-APINACA
- AB-FUBINACA
- AB-CHFUPYCA
- AB-CHMINACA
- AB-PINACA
- ADB-BINACA
- ADB-CHMINACA
- ADB-FUBINACA
- ADB-PINACA
- ADBICA
- APICA
- APINACA
- APP-FUBINACA
- MDMB-CHMICA
- MDMB-CHMINACA
- PX-3
References
- ↑ "Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA". The Journal of Pharmacology and Experimental Therapeutics 365 (2): 437–446. May 2018. doi:10.1124/jpet.117.246983. PMID 29549157. PMC 5932312. http://jpet.aspetjournals.org/content/early/2018/03/16/jpet.117.246983.
- ↑ "MDMB-FUBINACA". Cayman Chemical. https://www.caymanchem.com/Product.vm/catalog/16966.
- ↑ "Identification of new synthetic cannabinoid analogue APINAC (adamantan-1-yl 1-pentyl-1H-indazole-3-carboxylate) with other synthetic cannabinoid MDMB(N)-Bz-F in illegal products". Forensic Toxicology 35: 45–55. 2016. doi:10.1007/s11419-016-0331-z. ISSN 1860-8973.
- ↑ Buchler IP et al, "Indazole Derivatives", WO patent 2009106982
- ↑ "Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues". ACS Chemical Neuroscience 7 (9): 1241–54. September 2016. doi:10.1021/acschemneuro.6b00137. PMID 27421060.
- ↑ 3-methylvaline
- ↑ "Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group". Analytical and Bioanalytical Chemistry 407 (21): 6301–15. August 2015. doi:10.1007/s00216-015-8612-7. PMID 25893797.
- ↑ "Выступление председателя ГАК, директора ФСКН России В.П. Иванова на заседании ГАК 6 октября 2014 г." (in ru). Federal Drug Control Service of the Russian Federation. 6 October 2014. http://fskn.gov.ru/includes/periodics/speeches_fskn/2014/1006/124332682/detail.shtml.
- ↑ I. Bulygina (21 October 2014). "Clinical presentations of intoxication by new psychoactive compound MDMB(N)-Bz-F. Thesis of The II Scientific and Practical Seminar 'Methodical, Organizational and Law Problems of Chemical and Toxicological Laboratories of Narcological Services', Moscow" (in ru). http://www.narkotiki.ru/objects/narkotiki02/1414709242.ppt.
- ↑ "Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I". Drug Enforcement Administration. https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1221.htm.
- ↑ "Очередная жертва спайса" (in ru). Federal Drug Control Service of the Russian Federation. 17 March 2015. http://www.fskn.gov.ru/includes/periodics/news/2015/0317/205035975/detail.shtml.
- ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in zh). China Food and Drug Administration. 27 September 2015. http://www.sfda.gov.cn/WS01/CL0056/130753.html.
 |  |
